# Why is Eli Lilly and Company (LLY) stock trending?

November 18, 2026

Rumor.io reads what investors post about Eli Lilly and Company on X, Reddit, Stocktwits and YouTube and uses AI to summarize it each day. Updated November 17, 2026. Source: https://rumor.io/stocks/nyse-lly/questions

What people say, Nov 18:

- Eli Lilly's weight loss drug, Tirzepatide, has shown similar side effects to rival drug VK2735, with VK2735 able to match Tirzepatide's weight loss in as little as 33 weeks.
- Aarti Shah, former senior VP at Eli Lilly, has been appointed to the board of NVDA, a semiconductor company.
- Eli Lilly's weight loss drug, TZP, may lose market share to VKTX's Vanquish 2, which has shown more effective weight loss and better A1C results in clinical trials.

Eli Lilly and Company (LLY) has 0.4% of all stock attention on November 18, 2026, about 2.9x its 30-day average of 0.14%.

|  | Attention | 30-day average attention |
| --- | --- | --- |
| LLY | 0.4% | 0.14% |

Attention is the share of the likes, replies and reposts on posts about stocks.

## Is LLY stock sentiment bullish or bearish?

Sentiment on Eli Lilly and Company (LLY) is bullish on November 18, 2026: 60% of engagement on its posts is bullish, down from its 30-day average of 84%. That is level with all stocks (57%) and the Healthcare sector (62%).

|  | Bullish | Bearish |
| --- | --- | --- |
| LLY | 60% | 40% |
| LLY, 30-day average | 84% | 16% |
| Healthcare sector | 62% | 38% |
| All stocks | 57% | 43% |

The share of the likes, replies and reposts on bullish posts and on bearish posts, of the posts that took a side.

### What is the bull case for LLY stock?

What the bulls say, Nov 18:

- Eli Lilly is well-positioned for growth, with Novo Nordisk aiming to outpace its peers, including Lilly, in growth until 2030.
- The company's dividend payments have already been made, which will result in a significant decrease in dividend yield after FY26.
- Eli Lilly has a strong position in the pharmaceutical industry, with the benefits of AI likely to benefit companies like Pfizer, Merck, Novo, and Lilly, making them potential winners in the market.

Bulls hold 60% of engagement on Eli Lilly and Company (LLY) posts on November 18, 2026.

### What is the bear case for LLY stock?

What the bears say, Nov 17:

- Eli Lilly and Company's healthcare setup is one of the best next short candidates outside of bitcoin, recently losing its summer safe-haven bids.
- A hacker group is threatening to publish data allegedly belonging to 1.2 million Eli Lilly patients on the dark web, claiming to have obtained sensitive information including payment histories, medical diagnoses, names, and more.
- Eli Lilly and Company needs ~15% growth a year to 2036 to justify its stock price, but its Q3 price fell 15% and ~$2B of 2026 revenue is one-off, priced for a flawless decade.

Bears hold 40% of engagement on Eli Lilly and Company (LLY) posts on November 18, 2026.

## What are investors saying about LLY stock?

We train models to sort every post about Eli Lilly and Company into topics, then summarize what each group is saying. Each figure is the share of the engagement on LLY posts that went to that topic.

|  | Share of engagement | 30-day average share |
| --- | --- | --- |
| Announcements: company announcements | 92% | 5% |

### What has LLY announced?

What people say about LLY's announcements, Nov 17:

- Eli Lilly is expanding its weight-care program to allow US employers to cover the cost of FDA-approved GLP-1 medications from Novo Nordisk and Eli Lilly, starting January 2027.
- Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion to add an experimental antibody for rare blood cancers, with the deal including a cash payment and potential milestones.
- Eli Lilly has agreed to a $5.9 billion deal with private Stipple Bio for technology designed to tell cancer cells from healthy tissue, with the payment split between upfront and equity amounts.

Posts about company announcements drew 92% of the engagement on Eli Lilly and Company (LLY) posts on November 18, 2026, against a 30-day average of 5%.

## What is the latest news on LLY stock?

- [Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out](https://seekingalpha.com/article/4969748-rhythm-pharma-is-astrazeneca-eli-lilly-bidding-war-for-real-dont-rule-out) (Seeking Alpha, 8h ago): Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.
- [Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes](https://finance.yahoo.com/healthcare/articles/health-canada-approves-lillys-mounjaro-180000052.html) (Yahoo Finance, 10h ago)
- [Breakingviews - COMMENTARY: Eli Lilly’s $1.4 trln valuation is heavy with hope](https://www.reuters.com/commentary/breakingviews/eli-lillys-14-trln-valuation-is-heavy-with-hope-2026-11-18/) (Reuters, 23h ago)
- [Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR](https://seekingalpha.com/news/4673783-rythm-pharmaceuticals-gains-on-report-eli-lilly-made-150-share-offer-with-cvr) (Seeking Alpha, 1d ago): Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.
- [Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies](https://www.benzinga.com/news/health-care/26/11/63356680/eli-lilly-inks-multibillion-dollar-pact-to-develop-precision-cancer-therapies) (Benzinga, 1d ago)

## Who is talking about LLY stock?

97% of engagement on Eli Lilly and Company (LLY) posts on November 18, 2026 comes from people new to posting about it, up from a 30-day average of 35%.

|  | Newcomers | Regulars |
| --- | --- | --- |
| LLY | 97% | 3% |
| LLY, 30-day average | 35% | 65% |
| All stocks | 43% | 57% |

The share of the likes, replies and reposts on LLY posts that went to people new to posting about it and to regulars.

### What newcomers say (Nov 18)

- Eli Lilly's board of directors has a lack of technical expertise, with only one member having experience in the semiconductor industry.
- The company's weight-loss drug has been compared to the hype surrounding DeepSeek, with the author expressing skepticism about the sustainability of such "far-ahead" solutions.
- Eli Lilly's stock has been performing well, with the author expressing a bullish sentiment, predicting a price of $1,350 and considering buying more shares.

### What regulars say (Nov 18)

- Eli Lilly's Tirzepatide competitor, VK2735, has proven to match its weight loss results in as little as 33 weeks with a similar side effect profile, shifting the terminal weight loss curve to the left.
- Regulars expect Eli Lilly to continue growing, with Novo Nordisk aiming to outpace its peers, including Eli Lilly, in growth until 2030.
- Eli Lilly's stock price may be affected by its dividend payments, with some predicting a significant decrease after FY26.

## How does LLY compare with other Healthcare stocks?

We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each figure is that share.

Eli Lilly and Company (LLY) got the 5th most attention on social media of the Healthcare stocks on November 18, 2026: 3.9% of the attention on Healthcare stocks. The others with the most attention were SLS (29%), CAPR (7.9%), AKAN (6%) and UNH (4.2%).

|  | Share of Healthcare attention |
| --- | --- |
| [LLY](https://rumor.io/stocks/nyse-lly) | 3.9% |
| [SLS](https://rumor.io/stocks/nasdaq-sls) | 29% |
| [CAPR](https://rumor.io/stocks/nasdaq-capr) | 7.9% |
| [AKAN](https://rumor.io/stocks/nasdaq-akan) | 6% |
| [UNH](https://rumor.io/stocks/nyse-unh) | 4.2% |

### Which stocks are discussed alongside LLY?

People who post about Eli Lilly and Company (LLY) most often also post about NVO, MRK, VKTX, MTSR - Metsera, Inc., AMGN and NVS.

- [What are investors saying about NVO stock?](https://rumor.io/stocks/nyse-nvo): Novo Nordisk's stock price has fallen 72% from its June 2024 peak, but it still yields about 4.5% at the current price, higher than Coca-Cola's 2.1%.
- [What are investors saying about MRK stock?](https://rumor.io/stocks/nyse-mrk): Merck's termination of its Bellwave blood cancer program, including three Phase 3 trials, is seen as a major late-stage hematology asset loss.
- [What are investors saying about VKTX stock?](https://rumor.io/stocks/nasdaq-vktx): The company's lead molecule has substantial value today, and the rest of the company, net of cash, is not worth close to $1B.
- [What are investors saying about MTSR - Metsera, Inc. stock?](https://rumor.io/stocks/nasdaq-mtsr)
- [What are investors saying about AMGN stock?](https://rumor.io/stocks/nasdaq-amgn): Amgen's (AMGN) Prolia sales fell 44.5% year-over-year to $632 million in the quarter ended September 30, 2026, due to biosimilar competition.
- [What are investors saying about NVS stock?](https://rumor.io/stocks/nyse-nvs)

## What is Rumor.io?

Prices move on what people believe. Rumor.io measures what they are saying: it reads public posts about stocks, ETFs and crypto on X, Reddit, Stocktwits and YouTube, and reports what investors are talking about.

- What we read: 1.6 billion public posts about 7,500+ stocks, 6,600+ ETFs and 880+ cryptocurrencies, back to 2009.
- What we throw away: Social media is noisy. Our filters remove spam and bots, posts where the name means something else (Apple the fruit), and tickers that two assets share.

The summaries on this page are written by AI from public posts. The one under the heading is from the posts of November 18, 2026, and each of the others shows its own date. Updated November 17, 2026, the date of the oldest. The figures are counts of the posts and the reactions to them. They show what people are saying, which is not the same as what is true, and they do not predict a price.

Attention is an asset's share of the engagement on posts about all stocks. Engagement is the likes, replies and reposts a post receives. [How each metric is counted](https://rumor.io/docs/metrics). [More about Rumor.io](https://rumor.io).
